Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 13 (2004), Issue 1, Pages 39-43
http://dx.doi.org/10.1080/09629350410001664752

Monocyte chemoattractant protein-1 in patients with peripheral arterial disease

1Department of Immunology, Palacky University and Faculty Hospital, I. P. Pavlova str. 6, Olomouc 775 20, Czech Republic
2Department of Internal Medicine, Palacky University and Faculty Hospital, I. P. Pavlova str. 6, Olomouc 775 20, Czech Republic

Received 25 October 2003; Accepted 6 November 2003

Copyright © 2004 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Chemokine-driven migration of inflammatory cells has been implicated in the pathogenesis of atherosclerotic conditions including peripheral arterial disease (PAD). Monocyte chemoattractant protein-1 (MCP-1) is elevated in patients with coronary artery disease and in hypertensive patients. This study therefore investigated MCP-1 in patients with PAD.

Methods: Serum MCP-1 was determined by enzyme-linked immunosorbent assay in 36 healthy, control subjects and in 19 patients with PAD. Statistical analysis utilised the Mann-Whitney test and Spearman correlation (p<0.05).

Results: MCP-1 (pg/ml) was increased in patients compared with in controls (mean±standard error of the mean: PAD group, 748±60; control group, 459±27; p=0.0001). MCP-1 levels tended to decrease with progressing disease. From atherosclerosis risk factors, diabetes inclined to increase MCP-1 levels; hypertension had no effect. Serum MCP-1 correlated with cholesterol, triglycerides, low-density lipoprotein but not high-density lipoprotein.

Conclusion: Elevation of MCP-1 in the circulation of PAD patients shown in the present pilot study implicates this CC chemokine ligand 2 in inflammatory processes contributing to PAD clinical symptomatology. Further investigations are necessary to evaluate whether MCP-1 can be used as a potential marker of peripheral arterial disease follow-up and/or prognosis.